[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![Quantumup1 Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1060595604022280192.png) quantumup [@Quantumup1](/creator/twitter/Quantumup1) on x 3519 followers
Created: 2025-06-30 15:26:59 UTC

H.C. Wainwright🏁 $EWTX Buy-$42 and said, "Providing alternative approaches for inherited muscle disorders."
$BMY $CYTK $CAPR $SRPT
H.C. Wainwright added, "We are initiating coverage of Edgewise Therapeutics with a Buy rating and $XX price target.

Edgewise is a clinical-stage biotechnology company focused on developing orally delivered small molecule inhibitors for severe muscle diseases with significant unmet needs.

The company is currently advancing two candidates on its clinical pipeline: 
1) sevasemten, a selective, fast myofiber (type II) myosin inhibitor designed to protect contraction-induced muscle damage caused by dystrophinopathies, including Becker muscular dystrophy (BMD; data from the registrational GRAND CANYON cohort anticipated in 4Q26) and Duchenne muscular dystrophy (DMD; Phase X initiation anticipated in 2026); and
(2) EDG-7500, a novel, cardiac sarcomere modulator that aims to address impaired cardiac relaxation associated with both obstructive (oHCM) and non-obstructive (nHCM) forms of hypertrophic cardiomyopathy (longer-term Phase X CIRRUS-HCM Part D results anticipates in 2H25).

To date, both assets have exhibited well-tolerated safety profiles, favorable functional improvements, and positive clinical outcomes in their respective indications, and are poised to advance toward late-stage development.

We see potential for:
1) sevasemten to become the first approved drug for BMD, and an adjuvant for DMD SoC;
2) EDG-7500 as a valid alternative to cardiac myosin inhibitor (CMI)-mediated excessive heart function reduction; and
3) Edgewise as a valuable biopharmaceutical company providing a steady stream of meaningful clinical, regulatory, and commercial catalysts."


XXXXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1939707243730993340/c:line.svg)

**Related Topics**
[hc](/topic/hc)
[$srpt](/topic/$srpt)
[$capr](/topic/$capr)
[$ewtx](/topic/$ewtx)
[$bmy](/topic/$bmy)
[stocks healthcare](/topic/stocks-healthcare)
[$cytk](/topic/$cytk)
[sarepta therapeutics inc](/topic/sarepta-therapeutics-inc)

[Post Link](https://x.com/Quantumup1/status/1939707243730993340)